Stay updated with breaking news from Pierre Bedossa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers at the University of California San Diego School of Medicine have led a study to examine a potential new treatment option for patients with nonalcoholic steatohepatitis (NASH)-related fibrosis.
In the Phase IIb NATIVE, lanifibranor met both the primary and key secondary endpoints, including NASH resolution with no worsening of fibrosis and improvement of liver fibrosis with no worsening of NASHNATIVE
Press release content from Globe Newswire. The AP news staff was not involved in its creation.